Main container

Targeting the intratumoral microbiota to reverse therapeutic resistance in lethal prostate cancers - Studio del microbiota intratumorale nelle metastasi ossee da carcinoma prostatici letali per identificare nuovi bersagli terapeutici e invertire la resist

Title
Targeting the intratumoral microbiota to reverse therapeutic resistance in lethal prostate cancers - Studio del microbiota intratumorale nelle metastasi ossee da carcinoma prostatici letali per identificare nuovi bersagli terapeutici e invertire la resist
Code
PROCBIOME
Type
Sperimentale
Start Year
2024
Status
Terminato

Principal Investigator

Prof. Baldini Nicola

(Già professore Unibo e direttore Scienze e tecnologie biomediche e nanobiotecnologie IOR)

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more